Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06018571 · ClinicalTrials.gov registry record
Burden of Illness and Treatment Assessment of Patients With Dry Eye Disease: A Cross-Sectional Survey of Real-World Patients With Dry Eye Disease in the US
A clinical trial of Dry Eye Disease, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 946
- Enrollment target
- 1
- Study location
NCT06018571: Completed study of Dry Eye Disease, sponsored by Novartis Pharmaceuticals.
NCT06018571 is a study of Dry Eye Disease that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 946 participants, above the 226-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (319% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06018571, a study of Dry Eye Disease, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 946 participants
- Enrollment target
- 1
- Study location
Study Summary
This study employed secondary database analysis of the Adelphi Dry Eye Disease (DED) Disease Specific Programme™ (DSP™), a templatized cross-sectional survey with retrospective data collection that is administered by Adelphi to a convenience sample of patients diagnosed with DED, and their consulting physicians in the United States. In addition to the survey data, the DED DSP also included recorded medical history data as reported by physicians (optometrists, ophthalmologists or refractive surgeons).
Primary Outcome
Mean IDEEL score on Symptom Bother dimension: score range 0-100, where higher scores indicate greater bother. Mean IDEEL scores on Daily Activities, Emotional Impact, and Work dimensions: score range 0-100, where higher scores indicate lesser impact.
Conditions Studied
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 946 participants |
| Start Date | 2022-06-02 |
| Est. Completion | 2022-08-19 |
What the finished NCT06018571 record still lists
NCT06018571 is an observational study that tracks outcomes without assigning an intervention. The registered 946 participants enrollment target is mid-sized for trials with a published cap, above the 226-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (319% higher).
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 0 interventions.
NCT06018571 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06018571 about?
NCT06018571 is a clinical study titled "Burden of Illness and Treatment Assessment of Patients With Dry Eye Disease: A Cross-Sectional Survey of Real-World Patients With Dry Eye Disease in the US". This study employed secondary database analysis of the Adelphi Dry Eye Disease (DED) Disease Specific Programme™ (DSP™), a templatized cross-sectional survey with retrospective data collection that is administered by Adelphi to a convenience sample of patients diagnosed with DED, and their consultin...
What is the current status of trial NCT06018571?
This trial is currently completed. The enrollment target is 946 participants. The study started on 2022-06-02. Estimated completion is 2022-08-19.
What conditions does trial NCT06018571 study?
This clinical trial studies the following conditions: Dry Eye Disease.
Who is sponsoring clinical trial NCT06018571?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06018571 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06018571's enrollment target sits among peer trials
946 1st of 33 higher than 33 of 33 other Dry Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
RECRUITING · Phase 3
-
A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment
RECRUITING · Phase 4
-
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
RECRUITING · Phase 2
-
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
RECRUITING · Phase 2
-
2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD
RECRUITING
-
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06087224 · 947 participants · NA
The TELENEO Trial: A Multicenter Trial of Telemedicine for Advanced Neonatal Resuscitations in Community Hospitals
- NCT05020236 · 944 participants · Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- NCT04895709 · 949 participants · Phase 1
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
- NCT03784924 · 950 participants
EDRN Prostate MRI Biomarker Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI